Case studies

A top 10 pharma company partnered with ICON to improve study start-up in the U.S., shifting from an FTE model to unit-based delivery. Using proprietary systems and centralized teams, ICON reduced cycle times and identified further efficiency opportunities.

A pharma client partnered with ICON to support EU and US approval of a new diabetes therapy. ICON’s APS team sourced, labeled, and shipped comparator and study drugs for a complex phase 1 trial, helping meet the sponsor’s accelerated timeline.

In July 2024, a global biopharma client partnered with ICON to expand functional support. Starting with Clinical Operations and TMF roles, the partnership grew to over 60 FTEs and now includes Clinical Quality, Systems Experts, and Late Phase, with further expansion underway.

In February 2023, a global biopharma company added ICON to its vendor ecosystem, initially focusing on Clinical Operations. Within a year, ICON grew to represent 20.5% of total FSP resourcing, outperforming expectations and becoming a key partner. ICON has since expanded into multiple services, offering flexible commercial models and scalable support across the client’s evolving needs.

ICON developed, validated, and implemented a custom flow cytometric Receptor Occupancy Assay, delivering critical biomarker data for a complex monoclonal antibody clinical trial.

ICON successfully streamlined clinical operations during a post-market registry study by adapting sponsor SOPs mid-study, enabling a seamless transition to ICON-led project management while maintaining operational continuity and site performance.

A top 20 pharma subsidiary scaling plasma-derived therapies asked ICON to review their processes and plan for growth. With plasma reliant on donations, new centers were opening to meet demand and ensure patient access to life-saving treatments.

A small Asia-based biotech engaged ICON to manage its EU orphan drug designation submission for a treatment targeting Dercum’s disease. The designation was key to supporting a planned Phase 3 study and expanding into the EU, where the company had no existing presence.

A midsize pharma company based in the EU contracted ICON to support a New Drug Submission in Canada for a respiratory drug for chronic obstructive pulmonary disease

Symphony Health partnered with a social media company to develop a privacy-compliant ad measurement solution for a pharma client. Using machine learning, they maintained 90% accuracy while meeting stricter privacy standards—offering a scalable model for regulated environments.

Understanding Social Determinants of Health (SDOH) is key to addressing disparities and improving outcomes in Type 2 Diabetes. While factors like diet and access to care are known, quantifying their impact on diagnosis, treatment initiation, and adherence remains an emerging focus.

A pharma company partnered with Symphony Health to guide the launch of a TYK2 inhibitor for psoriasis. They explored market potential, free drug programs, treatment patterns, and prescribing behavior—especially among NPs and PAs—to shape positioning in a competitive landscape.